Scientific Program

May 2017 Symposium Learning Objectives

After attending this educational activity, participants will be able to:

  • Distinguish new and novel treatment options for patients with chronic lymphocytic leukemia
  • Identify new diagnostics and precision medicine platforms that can be utilized in the prognosis and treatment of lymphoma
  • Discuss integration of checkpoint inhibitors in the treatment of lymphoma
  • Evaluate treatment options for newly diagnosed and relapsed/refractory mantle cell lymphoma
  • Compare varied treatment options for diffuse large B-cell lymphoma
  • Recognize the important prognostic factors and treatment targets in Waldenströms Macroglobulinemia
  • Describe the current treatment options for patients with Hodgkin lymphoma

May 2017 Symposium Agenda

Friday, May 5, 2017    EXHIBITS OPEN 1:00 pm–6:15 pm
Time Session
12:00-1:00 pm REGISTRATION
1:00-1:10 pm Welcome and introduction
1:10-1:40 pm What is a Metabolic Tumor Volume and How may it be Leveraged in Lymphoma?
Lale Kostakoglu, MD, MPH
1:40-2:10 pm Checkpoint Inhibitors in Lymphoma: Rationale Incorporation into Treatment Paradigms
Leo Gordon, MD, FACP
2:10-2:40 pm Optimal Incorporation of New Targeted Agents in the Treatment of CLL
Jennifer Brown, MD, PhD
2:40-3:00 pm REFRESHMENT BREAK
3:00-3:30 pm Application of Precision Medicine in DLBCL
Samir Parekh, MBBS
3:30-4:00 pm Precision Medicine in T-NHL: Where are We Now?
Jaehyuk Choi, MD, PhD
4:00-5:00 pm SCIENTIFIC KEYNOTE:
Current Applications and Future Innovation in Cell Based Therapy
David Maloney, MD, PhD
5:00-6:15 pm ABSTRACT/POSTER HIGHLIGHTS AND WELCOME RECEPTION
   
Saturday, May 6, 2017     EXHIBITS OPEN 7:00 am–3:00 pm
Time Session
7:00-8:30 am REGISTRATION AND CONTINENTAL BREAKFAST
8:30-8:40 am Welcome and Introduction
8:40-9:10 am Circulating DNA Profiling for Lymphoma
Ash A. Alizadeh, MD, PhD
9:10-9:40 am Should PET Response Adapted Therapy be Utilized in the Therapy of NHL?
Martin Hutchings, MD, PhD
9:40-10:10 am Case Based Series: Frontline Treatment Approaches for MCL
Jonathon Cohen, MD, MS
10:10–10:30 am REFRESHMENT BREAK
10:30-11:00 am Case Based Series: How best to Manage Patients with Relapsed MCL
Jason Westin, MD
11:00 – 12:00pm CLINICAL KEYNOTE:
Current Status and Future Directions for Newly Diagnosed Hodgkin Lymphoma
Andreas Engert, MD
12:00-12:30 pm Should Pediatric AYAs with Hodgkin Lymphoma be Treated Differently than Adult AYAs?
Kara Kelly, MD
12:30-1:15 pm LUNCH
1:15-1:45 pm The Assessment and Treatment of Newly Diagnosed Waldenströms
Macroglobulinemia
Jorge Castillo, MD
1:45-2:15 pm How Do I Treat Limited Stage DLBCL?
Sonali Smith, MD
2:15-2:45 pm Novel Therapeutics for the Treatment of Relapsed/Refractory DLBCL
Daniel Landsburg, MD
2:45-3:00 pm Closing Remarks and Adjournment